LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Aandelen Lijst・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

8.27 -1.19

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.23

Max

8.27

Belangrijke statistieken
By Trading Economics
Inkomsten	-1.1B -722M
Verkoop	-250M 156M
K/W Sectorgemiddelde	7.603 49.701
EPS	0.141
Winstmarge	-461.478
Werknemers	435
EBITDA	-968M -702M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+181.42% upside

Dividenden
By Dow Jones
Volgende Winsten	3 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-83M 2.3B
Vorige openingsprijs	9.46
Vorige sluitingsprijs	8.27

Nieuwssentiment

By Acuity

50%

159 / 345 Rangschikking in Healthcare

BioCryst Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

25 mei 2026, 08:24 UTC

Belangrijke Marktbewegers

Acquisities, Fusies, Overnames

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 mei 2026, 21:22 UTC

Winsten

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 mei 2026, 20:50 UTC

Marktinformatie

Winsten

Basic Materials Roundup: Market Talk

25 mei 2026, 16:20 UTC

Marktinformatie

Winsten

Basic Materials Roundup: Market Talk

25 mei 2026, 16:01 UTC

Marktinformatie

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 mei 2026, 14:43 UTC

Marktinformatie

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 mei 2026, 14:15 UTC

Marktinformatie

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 mei 2026, 13:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

25 mei 2026, 12:58 UTC

Marktinformatie

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 mei 2026, 12:56 UTC

Marktinformatie

Winsten

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 mei 2026, 12:48 UTC

Marktinformatie

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 mei 2026, 12:48 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

25 mei 2026, 12:34 UTC

Marktinformatie

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 mei 2026, 12:10 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Delivery Hero's Assets Look Strategic -- Market Talk

25 mei 2026, 11:00 UTC

Marktinformatie

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 mei 2026, 10:19 UTC

Marktinformatie

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 mei 2026, 10:05 UTC

Winsten

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 mei 2026, 10:04 UTC

Winsten

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 mei 2026, 10:03 UTC

Winsten

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 mei 2026, 10:02 UTC

Winsten

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 mei 2026, 10:01 UTC

Winsten

Tenaga Nasional 1Q Net Up 3.7% on Year

25 mei 2026, 10:00 UTC

Winsten

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 mei 2026, 09:56 UTC

Winsten

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 mei 2026, 09:56 UTC

Winsten

Tenaga Nasional 1Q EPS MYR0.1883

25 mei 2026, 09:56 UTC

Winsten

Tenaga Nasional 1Q Rev MYR17.1B

25 mei 2026, 09:56 UTC

Winsten

Tenaga Nasional 1Q Net MYR1.1B

25 mei 2026, 09:38 UTC

Marktinformatie

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 mei 2026, 09:33 UTC

Marktinformatie

Global Equities Roundup: Market Talk

25 mei 2026, 09:33 UTC

Marktinformatie

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 mei 2026, 08:55 UTC

Marktinformatie

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Peer Vergelijking

Prijswijziging

BioCryst Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

181.42% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 23.33 USD 181.42%

Hoogste 32 USD

Laagste 13 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor BioCryst Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Gebaseerd op 7 analisten die aandelenratings hebben gegeven aan BioCryst Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

159 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.